Дослідження

Інформація в даному розділі отримана з ресурсу clinicaltrials.gov та оновлюється раз на три місяці

TitleStatusConditionsInterventionsSponsor/CollaboratorsStudy DesignsStart DateURL
A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative ColitisActive, not recruitingColitis, Ulcerative|Inflammatory Bowel DiseasesDrug: Placebo IV|Drug: Placebo SC|Drug: Ustekinumab IV|Drug: Ustekinumab SCJanssen Research & Development, LLCAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)July 10, 2015https://ClinicalTrials.gov/show/NCT02407236
Efficacy and Safety Study of Apremilast to Treat Active Ulcerative ColitisActive, not recruitingUlcerative ColitisDrug: Apremilast|Drug: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentDecember 10, 2014https://ClinicalTrials.gov/show/NCT02289417
BI 695501 Versus Humira in Patients With Active Crohn's Disease: a Trial Comparing Efficacy, Endoscopic Improvement, Safety, and ImmunogenicityActive, not recruitingCrohn DiseaseDrug: BI 695501|Drug: HUMIRABoehringer IngelheimAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentSeptember 28, 2016https://ClinicalTrials.gov/show/NCT02871635
Efficacy and Safety of Vedolizumab Subcutaneous (SC) as Maintenance Therapy in Crohn's DiseaseActive, not recruitingCrohn's DiseaseDrug: Vedolizumab SC 108 mg|Drug: Placebo|Drug: Vedolizumab IV 300 mgTakedaAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJanuary 4, 2016https://ClinicalTrials.gov/show/NCT02611817
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's DiseaseActive, not recruitingCrohn's DiseaseDrug: RPC1063CelgeneIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentOctober 9, 2015https://ClinicalTrials.gov/show/NCT02531113
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's DiseaseActive, not recruitingCrohn's DiseaseDrug: AdalimumabAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentApril 9, 2014https://ClinicalTrials.gov/show/NCT02065570
Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative ColitisActive, not recruitingUlcerative ColitisDrug: Etrasimod|Drug: PlaceboArena PharmaceuticalsAllocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: TreatmentNovember 2015https://ClinicalTrials.gov/show/NCT02536404
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative ColitisActive, not recruitingColitis, UlcerativeDrug: Vedolizumab|Drug: Adalimumab placebo|Drug: Adalimumab|Drug: Vedolizumab placeboTakedaAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJuly 15, 2015https://ClinicalTrials.gov/show/NCT02497469
Efficacy and Safety Study of RPC1063 in Ulcerative ColitisActive, not recruitingUlcerative ColitisDrug: RPC1063|Drug: placeboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentDecember 12, 2012https://ClinicalTrials.gov/show/NCT01647516
Long-Term Study Of CP-690,550 In Subjects With Ulcerative ColitisActive, not recruitingUlcerative ColitisDrug: CP-690,550PfizerAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentOctober 1, 2012https://ClinicalTrials.gov/show/NCT01470612
Study to Evaluate the Safety and Efficacy of Two Drug Regimens in Subjects With Moderate to Severe Ulcerative ColitisActive, not recruitingUlcerative Colitis (UC)Drug: Adalimumab|Other: PlaceboAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMarch 28, 2014https://ClinicalTrials.gov/show/NCT02065622
Extended Access Program of Vedolizumab IV in Ulcerative Colitis and Crohn's DiseaseActive, not recruitingColitis, Ulcerative|Crohn DiseaseDrug: VedolizumabTakedaIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentAugust 1, 2016https://ClinicalTrials.gov/show/NCT02743806
A Study of YM060 in Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)CompletedIrritable Bowel SyndromeDrug: YM060Astellas Pharma Inc|Astellas Pharma Europe B.V.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: TreatmentMarch 2005https://ClinicalTrials.gov/show/NCT00189813
Ibodutant for Relief of Irritable Bowel Syndrome (IRIS)CompletedIrritable Bowel SyndromeDrug: Ibodutant|Drug: PlaceboMenarini GroupAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentJuly 2008https://ClinicalTrials.gov/show/NCT00761007
A Double Blind Study for the Treatment of Acute Ulcerative ColitisCompletedUlcerative ColitisDrug: MesalamineWarner ChilcottAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJune 2006https://ClinicalTrials.gov/show/NCT00350415
A Study of TRK-170 for the Treatment of Crohn's DiseaseCompletedCrohn's DiseaseDrug: TRK-170|Drug: PlaceboToray Industries, IncAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentApril 2011https://ClinicalTrials.gov/show/NCT01345799
A Study Of Oral CP-690,550 As A Maintenance Therapy For Ulcerative ColitisCompletedUlcerative ColitisDrug: Placebo|Drug: CP690,550|Drug: CP-690,550PfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJuly 20, 2012https://ClinicalTrials.gov/show/NCT01458574
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's DiseaseCompletedCrohn's DiseaseDrug: Placebo|Drug: CP-690,550PfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentOctober 2011https://ClinicalTrials.gov/show/NCT01393626
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's DiseaseCompletedCrohn DiseaseBiological: CimziaUCB BIOSCIENCES GmbH|PPD|UCB PharmaIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentMay 2008https://ClinicalTrials.gov/show/NCT00552344
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's DiseaseCompletedCrohn DiseaseBiological: certolizumab pegol (CDP870, CZP)|Other: PlaceboUCB PharmaAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMarch 2008https://ClinicalTrials.gov/show/NCT00552058
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]CompletedCrohn's DiseaseBiological: Certolizumab Pegol (CDP870)UCB Pharma SA|UCB PharmaIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentJuly 2004https://ClinicalTrials.gov/show/NCT00160524
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's DiseaseCompletedCrohn DiseaseDrug: Sargramostim (Leukine)|Drug: PlaceboGenzyme, a Sanofi Company|SanofiAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double|Primary Purpose: TreatmentSeptember 2004https://ClinicalTrials.gov/show/NCT00206674
The Safety And Efficacy Of Maintenance Therapy With CP-690,550CompletedCrohn's DiseaseDrug: Placebo|Drug: CP-690,550PfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMarch 2012https://ClinicalTrials.gov/show/NCT01393899
A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's DiseaseCompletedCrohn's DiseaseBiological: Certolizumab Pegol (CDP870)UCB Pharma SA|UCB PharmaIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentFebruary 2004https://ClinicalTrials.gov/show/NCT00160706
A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's DiseaseCompletedCrohn's DiseaseDrug: CP-690,550PfizerAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentApril 2012https://ClinicalTrials.gov/show/NCT01470599
Extension Study of MT-1303 in Subjects With Crohn's DiseaseCompletedCrohn's DiseaseDrug: MT-1303Mitsubishi Tanabe Pharma CorporationIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentAugust 2015https://ClinicalTrials.gov/show/NCT02389790
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's DiseaseCompletedCrohn's DiseaseDrug: MT-1303|Drug: PlaceboMitsubishi Tanabe Pharma CorporationAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentMarch 2015https://ClinicalTrials.gov/show/NCT02378688
Efficacy and Safety of Vedolizumab Subcutaneously (SC) as Maintenance Therapy in Ulcerative ColitisCompletedColitis, UlcerativeDrug: Vedolizumab IV 300 mg|Drug: Placebo IV|Drug: Vedolizumab SC 108 mg|Drug: Placebo SCTakedaAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJanuary 8, 2016https://ClinicalTrials.gov/show/NCT02611830
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)CompletedUlcerative ColitisDrug: Mesalamine|Drug: PlaceboFerring PharmaceuticalsAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentFebruary 2016https://ClinicalTrials.gov/show/NCT02522780
Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)CompletedUlcerative ColitisDrug: Mesalamine|Drug: PlaceboFerring PharmaceuticalsAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentOctober 2015https://ClinicalTrials.gov/show/NCT02522767
Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative ColitisCompletedUlcerative ColitisDrug: Etrasimod|Drug: PlaceboArena PharmaceuticalsAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentJuly 2015https://ClinicalTrials.gov/show/NCT02447302
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative ColitisCompletedColitis, UlcerativeDrug: Placebo|Drug: JNJ-54781532 25 mg once daily|Drug: JNJ-54781532 75 mg once daily|Drug: JNJ-54781532 150 mg once daily|Drug: JNJ-54781532 75 mg twice dailyJanssen Research & Development, LLCAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentNovember 2013https://ClinicalTrials.gov/show/NCT01959282
Phase 2a Study to Evaluate the Safety/Tolerability and Efficacy of TOP1288 200 mg Rectal Solution Once Daily for 4 Weeks in Ulcerative ColitisCompletedUlcerative ColitisDrug: TOP1288|Drug: Placebo (for TOP1288)Topivert Pharma LtdAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentSeptember 2016https://ClinicalTrials.gov/show/NCT02888379
A Study Evaluating The Efficacy And Safety Of CP-690,550 In Patients With Moderate To Severe Ulcerative ColitisCompletedUlcerative ColitisDrug: tofacitinib|Drug: PlaceboPfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentApril 2012https://ClinicalTrials.gov/show/NCT01465763
A Study To Evaluate Both The Efficacy and Safety Profile of CP-690,550 In Patients With Moderately to Severely Active Ulcerative ColitisCompletedUlcerative ColitisDrug: tofacitinib|Drug: PlaceboPfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJune 2012https://ClinicalTrials.gov/show/NCT01458951
Randomized Placebo Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 mg in Patients With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA).CompletedUlcerative ColitisDrug: Budesonide|Drug: Placebo|Procedure: Procedure/Surgery: Blood sampling, endoscopyValeant Pharmaceuticals International, Inc.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentFebruary 2012https://ClinicalTrials.gov/show/NCT01532648
Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative ColitisCompletedUlcerative ColitisDrug: MesalaminTillotts Pharma AGAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentNovember 2009https://ClinicalTrials.gov/show/NCT01059344
A Study of MDX-1100 in Subjects With Active Ulcerative ColitisCompletedUlcerative ColitisBiological: sterile saline for injection|Biological: MDX-1100Bristol-Myers SquibbAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentApril 2008https://ClinicalTrials.gov/show/NCT00656890
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedColitis, UlcerativeBiological: Placebo|Biological: Golimumab 50 mg|Biological: Golimumab 100 mg|Biological: Golimumab 200 mgJanssen Research & Development, LLC|Merck Sharp & Dohme Corp.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentSeptember 2007https://ClinicalTrials.gov/show/NCT00488631
(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative ColitisCompletedUlcerative ColitisProcedure: Blood sampling, endoscopy|Drug: Budesonide MMX® 6 mg|Drug: Budesonide MMX® 9 mg|Drug: Entocort EC® 3 mg|Drug: PlaceboValeant Pharmaceuticals International, Inc.|Cosmo Technologies LtdAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJune 2008https://ClinicalTrials.gov/show/NCT00679380
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative ColitisCompletedColitis, UlcerativeBiological: Placebo|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg|Biological: Golimumab 400 mg|Biological: Golimumab 50 mgJanssen Research & Development, LLC|Merck Sharp & Dohme Corp.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentAugust 2007https://ClinicalTrials.gov/show/NCT00487539
Basiliximab in Moderate to Severe Ulcerative ColitisCompletedUlcerative ColitisDrug: BasiliximabCerimon PharmaceuticalsAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJanuary 2007https://ClinicalTrials.gov/show/NCT00430898
A Study to Evaluate the Accuracy of a Subset of the Length-109 Probe Set Panel (a Genetic Test) in Predicting Response to Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisCompletedColitis, UlcerativeBiological: GolimumabJanssen Research & Development, LLCIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentDecember 2013https://ClinicalTrials.gov/show/NCT01988961
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Crohn's Disease Who Completed the Studies M14-431 or M14-433Enrolling by invitationCrohn's DiseaseDrug: Upadacitinib|Drug: Placebo for UpadacitinibAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMarch 29, 2018https://ClinicalTrials.gov/show/NCT03345823
Filgotinib in Long-Term Extension Study of Adults With Crohn's DiseaseEnrolling by invitationCrohn's DiseaseDrug: Filgotinib|Drug: PlaceboGilead Sciences|Galapagos NVAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentMarch 17, 2017https://ClinicalTrials.gov/show/NCT02914600
Filgotinib in Long-Term Extension Study of Adults With Ulcerative ColitisEnrolling by invitationUlcerative ColitisDrug: Filgotinib|Drug: PlaceboGilead Sciences|Galapagos NVAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentFebruary 23, 2017https://ClinicalTrials.gov/show/NCT02914535
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Subjects With Ulcerative Colitis (UC)Enrolling by invitationUlcerative Colitis (UC)Drug: Upadacitinib (ABT-494)AbbVieAllocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentJanuary 31, 2017https://ClinicalTrials.gov/show/NCT03006068
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's DiseaseNot yet recruitingUlcerative Colitis|Crohn's DiseaseDrug: UTTR1147AGenentech, Inc.Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentJanuary 25, 2019https://ClinicalTrials.gov/show/NCT03650413
A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative ColitisNot yet recruitingColitis, UlcerativeDrug: Guselkumab Dose 1|Drug: Guselkumab Dose 2|Drug: Golimumab Dose 1|Drug: Golimumab Dose 2|Drug: PlaceboJanssen Research & Development, LLCAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentNovember 9, 2018https://ClinicalTrials.gov/show/NCT03662542
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable RemissionRecruitingUlcerative ColitisDrug: CP-690,500 5 mg|Drug: CP-690,550 10 mgPfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentNovember 16, 2017https://ClinicalTrials.gov/show/NCT03281304
A Study of Mirikizumab (LY3074828) in Participants With Active Crohn's DiseaseRecruitingCrohn's DiseaseDrug: Mirikizumab|Drug: PlaceboEli Lilly and CompanyAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentDecember 14, 2016https://ClinicalTrials.gov/show/NCT02891226
The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative ColitisRecruitingUlcerative ColitisDrug: cobitolimod|Drug: PlaceboInDex PharmaceuticalsAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJune 21, 2017https://ClinicalTrials.gov/show/NCT03178669
An Investigational Study of Experimental Medication BMS-986165 in Patients With Moderate to Severe Crohn's DiseaseRecruitingGranulomatous Colitis|Crohn's Disease|Crohn's Enteritis|Granulomatous EnteritisDrug: BMS-986165|Other: PlaceboBristol-Myers SquibbAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJune 25, 2018https://ClinicalTrials.gov/show/NCT03599622
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingCrohn's DiseaseDrug: Guselkumab Dose 1|Drug: Guselkumab Dose 2|Drug: Guselkumab Dose 3|Drug: Guselkumab Dose 4|Drug: Guselkumab Dose 5|Drug: Guselkumab|Drug: Ustekinumab|Drug: PlaceboJanssen Research & Development, LLCAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentApril 13, 2018https://ClinicalTrials.gov/show/NCT03466411
A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's DiseaseRecruitingCrohn DiseaseDrug: Ozanimod|Other: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJune 27, 2018https://ClinicalTrials.gov/show/NCT03464097
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseRecruitingCrohn DiseaseDrug: Ozanimod|Other: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMarch 7, 2018https://ClinicalTrials.gov/show/NCT03440385
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's DiseaseRecruitingCrohn DiseaseDrug: Ozanimod|Other: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentFebruary 27, 2018https://ClinicalTrials.gov/show/NCT03440372
Study To Evaluate The Efficacy And Safety Of Oral PF-06651600 And PF‑06700841 In Subjects With Moderate To Severe Crohn's DiseaseRecruitingCrohn's DiseaseDrug: Placebo PF-06651600|Drug: Placebo PF-06700841|Drug: PF-06651600|Drug: PF-06700841PfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentFebruary 2, 2018https://ClinicalTrials.gov/show/NCT03395184
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional Therapies But Have Not Failed Biologic TherapyRecruitingCrohn's DiseaseDrug: Upadacitinib|Drug: Placebo for UpadacitinibAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentDecember 7, 2017https://ClinicalTrials.gov/show/NCT03345849
A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's DiseaseRecruitingCrohn's DiseaseDrug: V565|Drug: PlaceboVHsquared Ltd.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentDecember 2016https://ClinicalTrials.gov/show/NCT02976129
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's DiseaseRecruitingCrohn's DiseaseDrug: Filgotinib|Drug: Placebo to match filgotinibGilead Sciences|Galapagos NVAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentOctober 2016https://ClinicalTrials.gov/show/NCT02914561
Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's DiseaseRecruitingCrohn DiseaseDrug: JNJ-64304500|Drug: Placebo|Drug: UstekinumabJanssen Research & Development, LLCAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentAugust 25, 2016https://ClinicalTrials.gov/show/NCT02877134
A Study of the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's DiseaseRecruitingCrohn's DiseaseDrug: placebo for risankizumab|Drug: risankizumab IV|Drug: risankizumab SCAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentMay 10, 2017https://ClinicalTrials.gov/show/NCT03105128
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989RecruitingCrohn's DiseaseDrug: placebo for risankizumab SC|Drug: risankizumab IV|Drug: placebo for risankizumab IV|Drug: risankizumab SCAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentApril 9, 2018https://ClinicalTrials.gov/show/NCT03105102
Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144RecruitingCrohn DiseaseDrug: etrolizumabHoffmann-La RocheAllocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentJune 8, 2015https://ClinicalTrials.gov/show/NCT02403323
A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)RecruitingCrohn DiseaseDrug: Etrolizumab|Drug: PlaceboHoffmann-La RocheAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentMarch 20, 2015https://ClinicalTrials.gov/show/NCT02394028
Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)RecruitingSmall Bowel Crohn's DiseaseDrug: Filgotinib|Drug: Placebo to match filgotinibGilead Sciences|Galapagos NVAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentApril 11, 2017https://ClinicalTrials.gov/show/NCT03046056
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic TherapyRecruitingCrohn's DiseaseOther: Matching placebo for upadacitinib|Drug: upadacitinibAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentNovember 29, 2017https://ClinicalTrials.gov/show/NCT03345836
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic TreatmentRecruitingCrohn's DiseaseDrug: placebo for risankizumab IV|Drug: risankizumab SC|Drug: risankizumab IVAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJanuary 3, 2018https://ClinicalTrials.gov/show/NCT03104413
A Safety Extension Study of SHP647 in Subjects With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA)RecruitingCrohn's Disease|Ulcerative ColitisDrug: 25 mg SHP647|Drug: 75 mg SHP647ShireAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentFebruary 27, 2018https://ClinicalTrials.gov/show/NCT03283085
Vedolizumab Subcutaneous Long-Term Open-Label Extension StudyRecruitingColitis, Ulcerative|Crohn DiseaseDrug: Vedolizumab SCTakedaAllocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentApril 15, 2016https://ClinicalTrials.gov/show/NCT02620046
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of UTTR1147A Compared With Placebo and With Vedolizumab in Participants With Moderate to Severe Ulcerative Colitis (UC)RecruitingUlcerative ColitisDrug: UTTR1147A|Drug: UTTR1147A Placebo|Drug: Vedolizumab|Drug: Vedolizumab PlaceboGenentech, Inc.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentOctober 26, 2018https://ClinicalTrials.gov/show/NCT03558152
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)RecruitingUlcerative ColitisDrug: Mirikizumab|Drug: PlaceboEli Lilly and CompanyAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJune 18, 2018https://ClinicalTrials.gov/show/NCT03518086
A Study to Assess the Efficacy and Safety of Risankizumab in Subjects With Ulcerative Colitis Who Responded to Induction Treatment in M16-067 or M16-065RecruitingUlcerative Colitis (UC)Drug: risankizumab|Drug: placebo for risankizumabAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentAugust 28, 2018https://ClinicalTrials.gov/show/NCT03398135
An Efficacy and Safety Study of SHP647 as Maintenance Therapy in Participants With Moderate to Severe Ulcerative ColitisRecruitingUlcerative ColitisDrug: SHP647|Other: PlaceboShireAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentApril 4, 2018https://ClinicalTrials.gov/show/NCT03290781
A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302)RecruitingUlcerative ColitisDrug: SHP647|Drug: PlaceboShireAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentOctober 31, 2017https://ClinicalTrials.gov/show/NCT03259308
Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative ColitisRecruitingUlcerative ColitisDrug: Filgotinib|Drug: Placebo|Drug: Standard of CareGilead Sciences|Galapagos NVAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJuly 11, 2017https://ClinicalTrials.gov/show/NCT03201445
Study to Compare Oral PF-06651600, PF-06700841 and Placebo in Subjects With Moderate to Severe Ulcerative ColitisRecruitingUlcerative ColitisDrug: PF-06651600 or Placebo|Drug: PF-06700841 or Placebo|Drug: PF-06700841|Drug: PF-06651600PfizerAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentFebruary 3, 2017https://ClinicalTrials.gov/show/NCT02958865
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative ColitisRecruitingUlcerative ColitisDrug: Filgotinib|Drug: Placebo to match filgotinibGilead Sciences|Galapagos NVAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentNovember 14, 2016https://ClinicalTrials.gov/show/NCT02914522
Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative ColitisRecruitingUlcerative ColitisDrug: RPC1063CelgeneIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentDecember 2, 2015https://ClinicalTrials.gov/show/NCT02531126
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative ColitisRecruitingUlcerative Colitis (UC)Drug: Upadacitinib (ABT-494)|Drug: PlaceboAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentOctober 29, 2018https://ClinicalTrials.gov/show/NCT03653026
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative ColitisRecruitingUlcerative ColitisDrug: RPC1063|Drug: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMay 31, 2015https://ClinicalTrials.gov/show/NCT02435992
A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Subjects With Moderately to Severely Active Ulcerative Colitis (UC)RecruitingUlcerative Colitis (UC)Drug: Placebo|Drug: Updacitinib (ABT-494)AbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentSeptember 26, 2016https://ClinicalTrials.gov/show/NCT02819635
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #2)RecruitingUlcerative ColitisDrug: Adalimumab|Other: Adalimumab Placebo|Drug: Etrolizumab|Other: Etrolizumab PlaceboHoffmann-La RocheAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentNovember 14, 2014https://ClinicalTrials.gov/show/NCT02171429
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1)RecruitingUlcerative ColitisDrug: Adalimumab|Other: Adalimumab Placebo|Drug: Etrolizumab|Other: Etrolizumab PlaceboHoffmann-La RocheAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentNovember 4, 2014https://ClinicalTrials.gov/show/NCT02163759
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) InhibitorsRecruitingColitis, UlcerativeDrug: Etrolizumab|Drug: PlaceboHoffmann-La RocheAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentAugust 12, 2014https://ClinicalTrials.gov/show/NCT02165215
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III StudiesRecruitingUlcerative ColitisDrug: EtrolizumabHoffmann-La RocheIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentSeptember 15, 2014https://ClinicalTrials.gov/show/NCT02118584
A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis Who Have Failed Prior Biologic TherapyRecruitingUlcerative Colitis (UC)Drug: risankizumab IV|Drug: placebo for risankizumab|Drug: risankizumab SCAbbVieAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentMarch 7, 2018https://ClinicalTrials.gov/show/NCT03398148
Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingUlcerative Colitis|Crohn's DiseaseDrug: VedolizumabTakedaAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentNovember 8, 2017https://ClinicalTrials.gov/show/NCT03138655
Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)RecruitingUlcerative Colitis|Crohn's DiseaseDrug: VedolizumabTakedaAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentJuly 30, 2018https://ClinicalTrials.gov/show/NCT03196427
Open-Label Extension Study of GSK1605786ATerminatedCrohn's DiseaseDrug: GSK1605786AGlaxoSmithKlineIntervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentApril 1, 2011https://ClinicalTrials.gov/show/NCT01318993
A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's DiseaseTerminatedCrohn's DiseaseDrug: GED-0301|Other: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJuly 25, 2016https://ClinicalTrials.gov/show/NCT02641392
Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's DiseaseTerminatedCrohn DiseaseDrug: GED-0301|Drug: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentDecember 8, 2015https://ClinicalTrials.gov/show/NCT02596893
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative ColitisTerminatedUlcerative ColitisDrug: PTG-100|Drug: Placebo groupProtagonist TherapeuticsAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: TreatmentDecember 2016https://ClinicalTrials.gov/show/NCT02895100
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's DiseaseTerminatedCrohn's DiseaseDrug: GSK1605786AGlaxoSmithKlineAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentNovember 11, 2011https://ClinicalTrials.gov/show/NCT01536418
GSK1605786A in the Maintenance of Remission in Subjects With Crohn's DiseaseTerminatedCrohn's DiseaseDrug: GSK1605786A|Drug: PlaceboGlaxoSmithKlineAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentMay 9, 2011https://ClinicalTrials.gov/show/NCT01316939
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's DiseaseTerminatedCrohn DiseaseDrug: Sargramostim (Leukine)|Drug: PlaceboGenzyme, a Sanofi Company|SanofiAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentJanuary 2006https://ClinicalTrials.gov/show/NCT00295165
Open-label Trial of Leukine in Active Crohn's DiseaseTerminatedCrohn DiseaseDrug: Sargramostim (Leukine)Genzyme, a Sanofi Company|SanofiAllocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: TreatmentFebruary 2003https://ClinicalTrials.gov/show/NCT00206700
Efficacy and Safety Study of GED-0507-34-Levo for Treatment of UCTerminatedUlcerative ColitisDrug: GED-0507-34-Levo 80 mg|Drug: GED-0507-34-Levo 160 mg|Drug: PlaceboPPM Services S.A.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentNovember 28, 2016https://ClinicalTrials.gov/show/NCT02808390
Safety and Efficacy of GS-5745 in Adults With Moderately to Severely Active Ulcerative ColitisTerminatedUlcerative ColitisBiological: GS-5745|Biological: PlaceboGilead SciencesAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentSeptember 2015https://ClinicalTrials.gov/show/NCT02520284
An Efficacy and Safety Study of Golimumab in Participants With Ulcerative ColitisTerminatedColitis, UlcerativeOther: Placebo|Drug: Golimumab 1 mg per kg|Drug: Golimumab 2 mg per kg|Drug: Golimumab 4 mg per kgJanssen Research & Development, LLC|Merck Sharp & Dohme Corp.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentAugust 2007https://ClinicalTrials.gov/show/NCT00488774
A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative ColitisTerminatedUlcerative ColitisDrug: visilizumabFacet Biotech|PDL BioPharma, Inc.Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentFebruary 2006https://ClinicalTrials.gov/show/NCT00279422
A Placebo-controlled Trial With rFXIII Administered to Subjects With Mild to Moderate Active Ulcerative ColitisTerminatedInflammation|Ulcerative ColitisDrug: catridecacog|Drug: placeboNovo Nordisk A/SAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: TreatmentOctober 2012https://ClinicalTrials.gov/show/NCT01706159
An Observational Follow-up Study for Subjects Receiving Salvage Therapy After Previous Treatment in a Visilizumab Study for Intravenous Steroid-Refractory Ulcerative ColitisTerminatedUlcerative ColitisDrug: Visilizumab (Nuvion®; HuM291)PDL BioPharma, Inc.|Facet BiotechTime Perspective: ProspectiveSeptember 2006https://ClinicalTrials.gov/show/NCT00355901
Study of Visilizumab Versus Placebo in Subjects With Intravenous Steroid-refractory Ulcerative Colitis Previously Responsive in a Visilizumab StudyTerminatedUlcerative ColitisDrug: visilizumabFacet Biotech|PDL BioPharma, Inc.Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentAugust 2006https://ClinicalTrials.gov/show/NCT00279435
A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's DiseaseWithdrawnCrohn DiseaseDrug: GED-0301|Drug: PlaceboCelgeneAllocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: TreatmentDecember 1, 2017https://ClinicalTrials.gov/show/NCT02974322

Здоров’я настільки переважує всі блага життя, що воістину здоровий жебрак щасливіший від хворого короля.
Артур Шопенгауер (1788 – 1860), німецький філософ

Адреса і контакти

Тел.: 097-772-98-28 Сучкова Екатерина Юрьевна
Тел.: 050-382-13-09 Сотскова Елена Анатольевна
Ел. пошта: info@gofulllife.com.ua
Facebook: gofulllife

Створено за підтимки біофармацевтичної компанії "Такеда Україна"